Clinical TrialsTENX recently reported extraordinary patient adherence in the ongoing Ph3 LEVEL trial with over 95% of randomized patients remaining on therapy.
Financial PerformanceAs of December 31, 2024, Tenax reported cash and cash equivalents of $94.9M, and in March 2025, the company raised an additional $25M in gross proceeds through a private placement.
Market PotentialKey asset TNX-103 has multi-billion dollar sales potential with forecasted sales of $2.2B, highlighting significant market opportunity.